Skip to Content
Merck
All Photos(3)

Key Documents

View All Documentation

V8138

Sigma-Aldrich

Vancomycin hydrochloride from Streptomyces orientalis

meets USP testing specifications

Synonym(s):

Vancomycin, Vancomycin HCL, Vancomycin Hydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(3)

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C66H75Cl2N9O24 · HCl
CAS Number:
1404-93-9
Molecular Weight:
1485.71
Beilstein/REAXYS Number:
3704657
UNSPSC Code:
51282703
PubChem Substance ID:
24278773
NACRES:
NA.76

biological source

Streptomyces orientalis

Quality Level

200

agency

USP/NF
meets USP testing specifications

storage condition

(Keep container tightly closed in a dry and well-ventilated place.)

concentration

≥900 μg/mg (as vancomycin base)

antibiotic activity spectrum

Gram-positive bacteria

application(s)

pharmaceutical (small molecule)

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

Cl[H].CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]2C[C@](C)(N)[C@@H](O)[C@@H](C)O2.CN[C@H](CC(C)C)C(=O)NC3[C@H](O)c4ccc(Oc5cc6Oc7ccc(cc7Cl)[C@@H](O)[C@H]8NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CC(N)=O)NC3=O)c(c5)c6)c9ccc(O)c(c9)-c%10c(O)cc(O)cc%10[C@@H](NC8=O)C(O)=O)c(Cl)c4

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Chemical structure: glycopeptide

Biochem/physiol Actions

Mode of action: Inhibits incorporation of terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides.

Antimicrobial Spectrum: Active against Gram-positive bacteria

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H317,H334

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000438499
0000437703
0000437704
0000437703
0000437704

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Celine Vidaillac et al.
The Journal of infectious diseases, 208(1), 67-74 (2013-03-30)
We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA). The
David W Eyre et al.
The Journal of infectious diseases, 209(9), 1446-1451 (2013-11-13)
Whole-genome sequencing was used to determine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomicin in pivotal phase 3 trials occurred by preventing relapse of the same infection, by preventing reinfection with a new strain, or by
Oliver A Cornely et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2493-2499 (2013-05-30)
Patients with cancer are at increased risk for Clostridium difficile-associated diarrhea (CDAD). Little is known about treatment response. Two double-blind trials randomly allocated 1,105 patients with CDAD to fidaxomicin or vancomycin treatment (modified intent-to-treat [mITT]), and 183 of these had
G Ralph Corey et al.
The New England journal of medicine, 370(23), 2180-2190 (2014-06-05)
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment. We conducted a randomized, double-blind trial in which adults with acute bacterial skin and skin-structure infections received either a single
Wessam Abdelhady et al.
The Journal of infectious diseases, 209(8), 1231-1240 (2014-01-10)
Staphylococcus aureus is the most common cause of endovascular infections. The staphylococcal accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant S. aureus (MRSA) persistence in such infections via its influence on biofilm formation.
View All Related Papers

Articles

Inhibition of Cell Wall Biosynthesis by Antibiotics

β-lactam antibacterials inhibit transpeptidase enzymes, preventing peptidoglycan assembly in both Gram-positive and Gram-negative bacteria.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service